Weight-Loss Medication Coverage in Virginia

Start here: the front entrance versus the backdoor

So, you’re wondering — “will my insurance cover Zepbound?” Good question. There are two ways to get weight-loss medication covered by your insurer, and we think of them as a front entrance and a backdoor. Most patients who are prescribed weight-loss medication are forced to try the front entrance. It consists of two gates, which work differently. You must get through both to have your medication covered.

Gate 1: Does your plan cover weight-loss drugs at all?

Some do; some don’t. It’s a benefits question, decided by whoever runs your plan — usually your employer. Many plans exclude weight-loss medications entirely. When that’s the case, no amount of documentation from your doctor will get the drug covered, because there’s nothing to approve. Cigna’s own policy states plainly that “weight loss medications are specifically excluded under many benefit plans.” UnitedHealthcare describes its weight-loss coverage program as “an optional program that is put in place for clients or businesses that have elected to cover weight loss products.”

Gate 2: Do you meet the clinical criteria?

If your plan does cover the drug you want, you are in luck. Now you must prove that you meet the medical criteria to be on it, which means prior authorization. Your doctor submits documentation, and the plan decides whether you qualify. Our qualifications page walks through the BMI and comorbidity thresholds in more detail.

Find your plan

Coverage rules differ enormously by who pays for your plan. Start with the guide that matches your situation, or read the fundamentals above first.

The building blocks of prior authorization

Nearly every Virginia plan builds its criteria from the same set of pieces. What differs is which pieces they use and how strict each one is.

• BMI threshold. The most common standard is 30 or higher, or 27 or higher with a weight-related condition. Some Virginia plans set the bar considerably higher.
• A qualifying weight-related condition. Typically high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, heart disease, knee osteoarthritis, fatty liver disease, PCOS, asthma, or COPD.
• A documented lifestyle attempt. Commonly 3 to 6 months of diet, exercise, and behavioral changes recorded in your chart. This is the requirement that most often trips people up — it must be documented, not just remembered.
• Step therapy. Some plans require you to try and fail a cheaper, older weight-loss drug first. Virginia Medicaid and TRICARE both require this.
• Age minimums. Zepbound is 18 and older. Wegovy injection and Saxenda can be approved starting at 12 in some plans.
• Proof it’s working. Almost every plan requires documented weight loss — usually at least 5% of your starting weight — before renewing. Saxenda is often held to 4% instead.
• Not doubling up. No plan will approve two GLP-1 medications at once.

Virginia plans at a glance

Criteria below are drawn from each plan’s current published authorization documents. Employer plans can and do vary from their carrier’s standard policy.

A note on timing

Several Virginia coverage rules changed on July 1, 2026, and more changes are scheduled:

• July 1, 2026 — state employee plans raised the BMI requirement to 35 and added a pharmacy deductible; Virginia Medicaid’s updated authorization form took effect; the Medicare GLP-1 Bridge launched; UnitedHealthcare’s updated commercial criteria took effect
• October 1, 2026 — Zepbound returns to CVS Caremark’s standard formulary
• Plan year 2027 — OPM expects FEHB carriers to require intensive behavioral therapy for anti-obesity medication coverage
• Plan year 2028 — Virginia’s new Essential Health Benefits benchmark plan application is pending with CMS

Frequently asked questions

The backdoor: coverage follows the diagnosis, not the drug

Here’s the thing almost nobody explains: the same medicine is sold under different brand names for different conditions, and your insurance treats those brand names completely differently. Tirzepatide is tirzepatide — but packaged as Zepbound it’s a weight-loss drug, or sometimes a sleep apnea medicine. Packaged as Mounjaro, it’s a diabetes drug. Semaglutide is semaglutide, but as Wegovy it’s for weight loss, and as Ozempic it’s for type 2 diabetes. Identical molecules, different labels.

This matters enormously, because when a plan excludes “weight-loss drugs,” that exclusion is written against the indication — the condition to be treated — not the molecule. Injectable diabetes medications, including semaglutide and tirzepatide, are covered under essentially every plan in Virginia, including Medicare Part D, which excludes weight-loss drugs outright.

The four backdoors

• Type 2 diabetes → Mounjaro or Ozempic. If you have T2DM, these are covered under standard pharmacy benefits, usually with far easier prior authorization than the weight-loss versions. This is not a workaround — it is the clinically correct prescription for someone with diabetes, and it happens to be the same active drug.
• Obstructive sleep apnea → Zepbound. Zepbound carries its own FDA approval for moderate-to-severe OSA in adults with obesity — generally a BMI of 30 or higher plus a sleep study documenting 15 or more apnea events per hour. Plans that exclude weight-loss drugs will often still cover this.
• Established cardiovascular disease → Wegovy. Wegovy is approved to reduce heart attack, stroke, and cardiovascular death in adults with known heart disease and obesity or overweight. That is a cardiovascular indication, not a weight-loss one.
• MASH liver disease → Wegovy injection. Approved for non-cirrhotic MASH with moderate-to-advanced fibrosis (stage F2 to F3). Most plans require specialist involvement and recent imaging or fibrosis testing.

The payers themselves point this out

TRICARE’s own authorization form instructs prescribers: “If patient is diabetic and meets the prior authorization criteria for Trulicity, Victoza, Ozempic, or Mounjaro, please consider these alternatives.” The plan is actively steering diabetic patients to the diabetes-labeled product.

Medicare does the same thing. The GLP-1 Bridge prior authorization form opens by telling prescribers that if the patient has obstructive sleep apnea, MASH with fibrosis, type 2 diabetes, or established cardiovascular disease, the request must go to the patient’s regular Part D plan instead of the Bridge — because those diagnoses are already Part D–eligible.

Why not get evaluated?

These “backdoor” conditions are genuinely underdiagnosed in people with obesity. Obstructive sleep apnea in particular often goes unrecognized for years — if you snore, wake unrefreshed, or are drowsy during the day, ask about a sleep study. An A1c test will tell you where you stand on diabetes. You may already qualify and not know it.

A few practical limits to be aware of:

• Prediabetes is not diabetes. It may help you meet a comorbidity requirement for Wegovy or Zepbound, but it does not open the Mounjaro or Ozempic door.
• You cannot be on two GLP-1s at once. Every Virginia plan reviewed here blocks concurrent GLP-1 therapy.
• Doses aren’t identical across brands. Ozempic tops out at 2 mg while Wegovy goes to 2.4 mg (and Wegovy HD to 7.2 mg). Mounjaro and Zepbound both reach 15 mg.
• TRICARE blocks the reverse direction. Its form states that non-FDA-approved uses “are not approved including diabetes mellitus” — you cannot get Wegovy or Zepbound covered by citing diabetes.
• Formulary tiers differ. Being covered under a diabetes indication doesn’t guarantee a low copay.

What to say to your doctor: “My plan excludes weight-loss drugs. Do I have any other condition — sleep apnea, diabetes, heart disease, fatty liver — that these medications are approved to treat? And should I be tested for any of them?”

Sources

• Virginia DMAS Service Authorization Form: Weight-Loss Management, effective 07/01/2026
• Anthem HealthKeepers Plus Prior Authorization Form: Weight-Loss Management (VABCBS-CD-091232-25)
• Virginia DHRM, Open Enrollment Spotlight 2026 and State Employee Health Plan Update to the Senate Finance and Appropriations Committee, April 14, 2026
• Sentara Health Plans Pharmacy Prior Authorization/Step-Edit Request, Weight Management Drugs (CORE), revised 6/11/2026
• Cigna Coverage Policy IP0206, Weight Loss – GLP-1 Agonists BMI ≥ 30, effective 06/01/2026
• UnitedHealthcare Clinical Pharmacy Program 2026 P 1114-21, effective 7/1/2026
• Aetna Pharmacy Clinical Policy Bulletins, weight-loss and anti-obesity agents
• CMS, Medicare GLP-1 Bridge program page and prior authorization request form
• TRICARE Prior Authorization Request Form for semaglutide (Wegovy) and tirzepatide (Zepbound Pen Injector), dated 15 July 2026
• OPM FEHB carrier guidance, plan years 2026 and 2027
• Virginia Joint Commission on Health Care, Obesity and Eating Disorders Prevention and Treatment in Virginia; Virginia State Corporation Commission Bureau of Insurance, Essential Health Benefits Benchmark Plan